Physician profile
Robert Walley
NPI 1588047567
$7,642.71
in general payments reported to CMS, 2019-2025
27 companies · $5,632 in 2025
The $5,632 reported for 2025 was more than what 93% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $67.41 · 2021: $687 · 2022: $262 · 2023: $159 · 2024: $414 · 2025: $5,632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,000 · Food and Beverage: $1,281 · Travel and Lodging: $924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,000.00 |
| Food and Beverage | $1,280.86 |
| Travel and Lodging | $924.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,924.31 | 2025 | |
| Glaxosmithkline, LLC. | $517.16 | 2021-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $233.98 | 2019-2025 | Tezspire |
| Viatris Specialty LLC | $230.72 | 2025 | Yupelri |
| Grifols USA, LLC | $198.79 | 2025 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $185.00 | 2019-2022 | |
| Mylan Specialty L.P. | $171.51 | 2020-2024 | Yupelri |
| Abiomed | $159.45 | 2023 | Impella |
| Genentech USA, INC. | $122.14 | 2019 | |
| Insmed, INC. | $122.05 | 2019-2021 | |
| Pulmonx Corporation | $121.43 | 2021 | |
| United Therapeutics Corporation | $85.23 | 2024-2025 | Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.08 | 2021-2025 | Ofev |
| Abbvie INC. | $64.79 | 2021-2022 | |
| Amgen INC. | $57.52 | 2024-2025 | Tezspire |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $52.94 | 2024 | Purified Cortrophin Gel |
| Genzyme Corporation | $49.21 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $48.86 | 2021-2024 | Dupixent |
| Merck Sharp & Dohme LLC | $44.24 | 2024-2025 | Zerbaxa |
| Jazz Pharmaceuticals INC. | $43.68 | 2021-2025 | |
| Ethicon INC. | $33.20 | 2019 | |
| Shionogi INC | $21.44 | 2025 | Fetroja |
| Baxter Healthcare | $19.14 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Alexion Pharmaceuticals, INC. | $18.44 | 2021 | |
| La Jolla Pharmaceutical Company | $16.06 | 2024 | Giapreza |
| Philips North America LLC | $14.63 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Walley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.